The product pipeline is crucial to the long-term success of any pharmaceutical company. At Otsuka America Pharmaceutical, Inc., we are fortunate to draw from a number of different sources for our healthcare product pipeline. The company currently has three general sources for new products:

• Otsuka Pharmaceutical Co., Ltd. (OPC), OAPI's corporate affiliate, is one of the largest healthcare companies in Japan. OPC has 29 research institutes worldwide which conduct most of the company's basic research, product development, and toxicology research and development studies. In addition to the OPC research institutes, the Otsuka Pharmaceutical Group owns a number of other businesses engaged in healthcare product development. Otsuka America Pharmaceutical, Inc. is developing products discovered by Otsuka Pharmaceutical Co. Ltd.
  
  
  
• In addition Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) is dedicated to research, product development, and clinical development. The professionals now with OPDC were invaluable contributors to the development of ABILIFY^® (aripiprazole)Tablets ¹ and PLETAL^®  (cilostazol) Tablets ² as well as the clinical development of other Otsuka products. To learn more about clinical trials being conducted by Otsuka, please visit the U.S. National Institute of Health clinical trials registry website, www.clinicaltrials.gov.
  
  
  
  
• OAPI seeks out products from reputable businesses outside the Otsuka Pharmaceutical Group for development and commercialization.